Incyte announced new Phase 3 frontMIND findings evaluating tafasitamab + lenalidomide and R-CHOP in patients with newly diagnosed high-intermediate and high-risk diffuse large B-cell lymphoma (DLBCL). Presented at ASCO 2026, the pivotal frontline study investigates whether adding the CD19-targeted monoclonal antibody tafasitamab to standard chemoimmunotherapy can improve outcomes in first-line DLBCL. The company stated that the results support planned global regulatory submissions.

Tafasitamab (Monjuvi/Minjuvi)

  • Manufacturer: Incyte Corporation
  • Drug Type: Humanized Fc-modified cytolytic CD19-targeting monoclonal antibody
  • Therapeutic Area: Hematologic oncology
  • Disease Focus: Diffuse Large B-Cell Lymphoma (DLBCL)
  • Mechanism of Action
    • Target: CD19
      • CD19 = B-cell surface antigen targeted by tafasitamab
    • Mechanistic Design:
      • Humanized monoclonal antibody
      • Fc-modified to enhance cytolytic immune activity
    • Intended Biological Effect:
      • Targeting CD19-expressing malignant B cells to drive anti-tumor immune killing

FrontMIND Study Design (NCT04824092)

  • Method: Phase 3, multicenter, randomized, double-blind, placebo-controlled trial
  • Study Objective: Evaluate the efficacy and safety of the tafasitamab (tafa) + lenalidomide (Len) + R-CHOP in first-line DLBCL
  • Participants: Adult patients with newly diagnosed DLBCL
    • Particularly, previously untreated, high-intermediate, and high-risk patients
  • Readout Categories: low-, intermediate-, or high-risk for urothelial carcinoma

ASCO 2026, Oral Abstract #7000

Positive Phase 3 FrontMIND results will be presented by Dr. Georg Lenz, MD, PhD, on May 30th at the American Society of Clinical Oncology (ASCO) 2026 Annual Meeting as an oral abstract session.

  • Conference Presentation: 2026 ASCO Annual Meeting, Oral Abstract Session, Hematologic Malignancies: Lymphoma and Chronic Lymphocytic Leukemia.
  • Abstract Title: FrontMIND: Phase 3 Study of tafasitamab (Tafa) Plus lenalidomide (Len) and R-CHOP for Patients (pts) with Newly Diagnosed Diffuse Large B-cell Lymphoma (DLBCL)

Clinical Implications

  • ✔ These results support global regulatory submissions.

Sources:

  1. Incyte. Incyte highlights new Phase 3 tafasitamab data at the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting [press release]. April 21, 2026. Accessed May 17, 2026. https://investor.incyte.com/node/26476/pdf
  2. ClinicalTrials.gov. Tafasitamab + lenalidomide + R-CHOP versus R-CHOP in newly diagnosed high-intermediate and high risk DLBCL patients (frontMIND). ClinicalTrials.gov identifier: NCT04824092. Updated April 1, 2026. Accessed May 17, 2026. https://clinicaltrials.gov/study/NCT04824092